newsfilter
← Latest News
GlobeNewswire·

RenovoRx Establishes RenovoCath® Medical Advisory Board

  • RenovoRx, Inc. (NASDAQ: RNXT) announced the formation of a dedicated RenovoCath Medical Advisory Board (MAB) on February 10, 2026, to support clinical & strategic initiatives.
  • The MAB comprises leading US interventional radiology experts who will provide insights to advance the Trans-Arterial Micro-Perfusion (TAMP) therapy platform in indications with high unmet medical needs.
  • The board will guide ongoing clinical & market strategies, including investigator-initiated trials for borderline resectable & metastatic pancreatic cancer designed to broaden TAMP applications.
  • Initial MAB members include Dr. Nadine Abi-Jaoudeh (UCI Health), Dr. Mustafa Al-Roubaie (Moffitt Cancer Center), Dr. Khashayar Farsad (Oregon Health & Science University), Dr. Ripal Gandhi (Baptist Health South Florida), Dr. Paula Marie Novelli (UPMC), & Dr. Jonathan Kessler (City of Hope).
  • RenovoRx is actively commercializing RenovoCath as a standalone device, having generated approximately $900,000 in revenue from sales during the first nine months of 2025.
  • The company is evaluating its drug-device combination candidate IAG (intra-arterial gemcitabine via RenovoCath) in the Phase III TIGeR-PaC trial for locally advanced pancreatic cancer.
  • IAG received Orphan Drug Designation for pancreatic cancer & bile duct cancer, granting seven years of market exclusivity upon FDA approval.
  • RenovoCath is an FDA-cleared device intended for isolating blood flow & delivering fluids to peripheral vascular sites, as well as for temporary vessel occlusion.